1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Sophiris Targets Prostate Cancer With Modified Biologic

 
• By Mike Ward

Nearly 140,000 men each year are diagnosed with localized prostate cancer, and the common treatment is radical - surgical removal of the prostate or whole organ radiation. Sophiris Bio is a San Diego-based biotech developing topsalysin for the focal treatment of localized prostate cancer, and may spare the organ from such massive collateral damage. Speaking at the Biotech Showcase, Sophiris CEO Randall Woods explained to Scrip how topsalysin works and how he is looking to continue clinical development of the biologic, in both localized prostate cancer and benign prostatic hyperplasia.

Video interview

C#200400833:Sophiris Bio Inc.] is expecting 2018 to be a pivotal year for the company. It aims to unveil data relating to a Phase IIb trial of topsalysin in localized prostate cancer, complete preparation for a single Phase III registration trial for the indication, as well as look for support to develop the biologic as a treatment for benign prostatic hyperplasia, which has completed one Phase III trial.

While the company has funds to complete the Phase II trial it is looking for additional funds and partners to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

More from Therapy Areas

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.